By: Menéndez S.J.R. No. 17

A JOINT RESOLUTION

- 1 proposing a constitutional amendment providing for the
- 2 establishment of the Texas Research Consortium to Cure Infectious
- 3 Diseases (TRANSCEND) and authorizing the issuance of general
- 4 obligation bonds to fund collaborative research on and development
- 5 of infectious disease treatments and cures for humans.
- 6 BE IT RESOLVED BY THE LEGISLATURE OF THE STATE OF TEXAS:
- 7 SECTION 1. Article III, Texas Constitution, is amended by
- 8 adding Section 69 to read as follows:
- 9 Sec. 69. (a) In this section:
- 10 (1) "Consortium" means the Texas Research Consortium
- 11 to Cure Infectious Diseases (TRANSCEND).
- 12 (2) "Disease" means a disorder of structure or
- 13 function in a human that produces specific signs or symptoms or
- 14 affects a specific location in the human body and that has the
- 15 potential of being prevented by a vaccine or otherwise treated or
- 16 cured.
- 17 (b) The legislature by general law shall establish the Texas
- 18 Research Consortium to Cure Infectious Diseases (TRANSCEND) to:
- 19 <u>(1) award grants to public or private persons or</u>
- 20 <u>entities for the purpose of:</u>
- 21 (A) conducting collaborative research on
- 22 <u>infectious diseases and associated conditions and innovative</u>
- 23 methods to prepare for infectious disease outbreaks;
- 24 (B) developing treatments and cures, including

- 1 vaccines, for diseases and associated conditions;
- 2 (C) developing education initiatives and
- 3 conducting outreach to engage and inform the public on infectious
- 4 diseases and associated conditions; and
- 5 (D) developing initiatives to prepare for and
- 6 rapidly respond to infectious disease outbreaks and public health
- 7 crises;
- 8 (2) establish a centralized research location through
- 9 which the consortium will operate and facilitate collaborative
- 10 research on infectious diseases and related disorders and the
- 11 development of treatments and cures for infectious diseases; and
- 12 (3) establish appropriate standards and oversight
- 13 bodies for the consortium to ensure money authorized by this
- 14 section is properly used for infectious disease research and
- 15 preparation and for development of infectious disease treatments
- 16 <u>and cures.</u>
- 17 (c) The legislature by general law shall establish for the
- 18 consortium a governing body and any other decision-making body the
- 19 legislature determines appropriate to govern the consortium. The
- 20 members of the governing body and other decision-making body of the
- 21 consortium serve terms of not more than four years.
- 22 (d) The legislature by general law may authorize the Texas
- 23 Public Finance Authority to provide for, issue, and sell general
- 24 obligation bonds of the State of Texas on behalf of the consortium
- 25 in an amount not to exceed \$3 billion and to enter into related
- 26 credit agreements. The Texas Public Finance Authority may not
- 27 issue more than \$300 million in bonds authorized by this subsection

- 1 in any state fiscal year. The bonds shall be executed in the form,
- 2 on the terms, and in the denominations, bear interest, and be issued
- 3 in installments as prescribed by the Texas Public Finance
- 4 Authority.
- 5 (e) Proceeds from the sale of the bonds shall be deposited
- 6 in separate funds or accounts, as provided by general law, within
- 7 the state treasury to be used by the consortium to implement this
- 8 section.
- 9 (f) Notwithstanding any other provision of this
- 10 constitution, the consortium, which is established in state
- 11 government, may use the proceeds from bonds issued under Subsection
- 12 (d) of this section and any federal or private grants and gifts to:
- 13 (1) provide grants for the purposes described by
- 14 Subsection (b)(1) of this section;
- 15 (2) purchase, subject to approval by the governing
- 16 body and any other decision-making body of the consortium, research
- 17 and laboratory facilities by or on behalf of a grant recipient; and
- 18 (3) operate the consortium.
- 19 (g) The proceeds from bonds issued under Subsection (d) of
- 20 this section may be used to pay the costs of issuing the bonds and
- 21 any administrative expense related to the bonds.
- (h) While any bond or interest on a bond authorized by this
- 23 section is outstanding and unpaid, from the first money deposited
- 24 to the state treasury in each state fiscal year not otherwise
- 25 appropriated by this constitution, an amount sufficient to pay the
- 26 principal of and interest on bonds that mature or become due during
- 27 the year and to make payments that become due under a related credit

- 1 agreement during the year is appropriated for purposes of this
- 2 section, less the amount in the sinking fund at the close of the
- 3 previous state fiscal year.
- 4 (i) A bond issued under this section, after approval by the
- 5 attorney general, registration by the comptroller of public
- 6 accounts, and delivery to the purchasers, is incontestable and is a
- 7 general obligation of this state under this constitution.
- 8 (j) Before the consortium may make a grant of any proceeds
- 9 of bonds issued under this section, the recipient of the grant must
- 10 have an amount of money equal to one-half the amount of the grant
- 11 dedicated to the research that is the subject of the grant request.
- 12 (k) The Texas Public Finance Authority shall consider using
- 13 a business whose principal place of business is located in this
- 14 state to issue the bonds authorized by this section, including
- 15 using a historically underutilized business as defined by general
- 16 <u>law.</u>
- 17 SECTION 2. This proposed constitutional amendment shall be
- 18 submitted to the voters at an election to be held November 2, 2021.
- 19 The ballot shall be printed to permit voting for or against the
- 20 proposition: "The constitutional amendment providing for the
- 21 establishment of the Texas Research Consortium to Cure Infectious
- 22 Diseases (TRANSCEND) and authorizing the issuance of up to \$3
- 23 billion in general obligation bonds to fund collaborative research
- 24 on and development of infectious disease treatments and cures for
- 25 humans."